GoKawiilEli Lilly's retatrutide shown to reduce sleep apnea episodes in trials
Two clinical trials found that Eli Lilly's experimental obesity drug retatrutide significantly cut the number of apnea episodes experienced by participants compared with those given a placebo. Retatrutide is already being studied as a potent weight-loss treatment, and the apnea findings represent an additional effect observed during testing.
GoKawiil's interpretation of the reporting above, not reported fact.
Sleep apnea is closely linked to obesity, so a drug that addresses both weight and breathing disruptions during sleep could appeal to a broader range of patients and prescribers. If confirmed in further studies, this could strengthen Lilly's competitive position against other obesity-drug makers by offering a dual-benefit treatment, though the results so far come from a limited set of trials.
- Retatrutide reduced apnea episodes versus placebo in two trials.
- The drug is already positioned as a leading candidate in the obesity treatment market.
- Further research would be needed to confirm the apnea benefit before any regulatory claims could be made.
Source: gizmodo.com, 2026-10-26
Published there as: “The Most Powerful Obesity Drug Yet Has a Hidden Benefit—and It Happens While You Sleep”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.